RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets

Abstract

RNAactDrug 2.0 (available at https://bio-bigdata.hrbmu.edu.cn/RNAactDrug or https://bio-datamining.hrbmu.edu.cn/RNAactDrug) is an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. We have updated the RNAactDrug 2.0 database with significantly expanded data and improved features, including (i) ∼30 000 drugs, 38 908 RNA molecules, and 22 800 375 drug–RNA associations from large-scale pharmacogenomic databases, covering four molecular layers: expression, copy number variation (CNV), mutation, and methylation; (ii) 11 099 cases from The Cancer Genome Atlas across 33 cancer types are integrated to support clinical and pan-cancer analyses of drug sensitivity-associated RNA features; (iii) ∼3.8 million cells from >200 single-cell RNA sequencing datasets, spanning 34 cancer types and 38 tissues, enable analysis of cell type-specific patterns and intratumoral heterogeneity; (iv) 26 440 enhancers and 788 444 drug-enhancer associations, combined with potential target prediction, provide an exploratory epigenetic regulatory dimension; (v) enhanced search and browsing functionalities, together with seven tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer-related analyses. In summary, RNAactDrug 2.0 is a crucial resource for the multi-omics dissection of drug sensitivity-associated molecules, providing important support for the discovery of drug resistance biomarkers and the advancement of personalized therapeutic strategies.